---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-095317"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:47:26.264232+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD posts $1.1M net income from continuing ops in FY2022 vs loss of $79.3M in 2021

## Summary
- License revenue surged to $70.0M from $2.6M, driven by $140M upfront from Mayne Pharma transaction.
- Company repaid all $188.3M debt, redeemed Series A preferred stock, and has $38.1M cash on hand.
- Discontinued ops generated $80.7M product revenue; net income of $110.9M vs loss in 2021.
- Reduced to one full-time employee; transition to virtual royalty model from Mayne Pharma license.
- Eligible for up to $30M milestones and 7.5%-8% royalties for 20 years with $3M minimum annual royalties.

## SEC filing metadata
- accession: 0001193125-23-095317
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/0001193125-23-095317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/d485631d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-095317
- JSON: https://secwatch.observer/filing/0001193125-23-095317.json
- Plain text: https://secwatch.observer/filing/0001193125-23-095317.txt

## Key facts
- Earnings Releases
  TherapeuticsMD, Inc. reported the full year ended December 31, 2022 results: revenue $70.0 million, net income $1.1 million, EPS $0.12 per basic share.
  - Period: the full year ended December 31, 2022
  - Revenue: $70.0 million
  - Net income: $1.1 million
  - EPS: $0.12 per basic share
  - Result: reported results
  source text: License Revenues from Continuing Operations • License revenues from continuing operations, which are revenues from continuing operations related to license agreements, were $70.0 million for the year ended December 31, 2022, compared to $2.6 million for 2021. The increase in license revenues was a result of the allocation of the initial upfront payment and
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/0001193125-23-095317-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.